A study of CBDV (Cannabidivarin) for the treatment of autism spectrum disorders.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2016 According to a GW Pharmaceuticals media release, the company expects to initiate this trial in the third quarter of 2017.
- 31 Aug 2016 New trial record
- 10 Aug 2016 According to a GW pharmaceuticals media release, the company expected to commence thsi study in H1 of 2017.